Details of the Drug
- Generic Name:
- Drug Type:
- Kinase inhibitor (STAMP [Specifically Targeting the ABL Myristoyl Pocket] inhibitor)
- How the Drug is Given:
Indications and Usage
Asciminib is indicated for the treatment of adult patients with:
- Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).
This indication is approved under accelerated approval based on major molecular response (MMR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
- Ph+ CML in CP with the T315I mutation.
Side effects needing medical attention
Most common adverse reactions are upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.